Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Philip W. Kantoff, MD
|
|
Give Review
Philip Kantoff works in the field of Oncology. He attended NYU School of Medicine. He received awards:"America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer", "Boston Herald" and "Super Doctor". Philip Kantoff is also published. He has 102 publications published. The lastest publication: "Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply.' He accepts all Medicare patients.
Publications
- Imaging yield from 133 consecutive patients with prostate Cancer and low trigger PSA from a single institution.
- A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate Cancer treated with abiraterone acetate after doceta...
- Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate Cancer aggressiveness at diagnosis.
- The androgen receptor cistrome is extensively reprogrammed in human proState tumorigenesis.
- ProState-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.
- Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
- Associations of prostate Cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.
- Development and Clinical Validation of an in situ Biopsy Based Multi-Marker Assay for Risk Stratification in Prostate Cancer.
- Identifying suicidal symptoms in prostate Cancer survivors using brief self-report.
- Abiraterone treatment in castration-resistant prostate Cancer selects for progesterone responsive mutant androgen receptors.
- Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
- The Role of miRNAs in Prostate Cancer.
- Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared with Gleason 8 Disease.
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results.
- The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate Cancer.
- Role of diet in prostate Cancer: the epigenetic link.
- Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate Cancer.
- Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer.
- Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma.
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T.
- Contemporary Nationwide Patterns of Self-reported ProState-Specific Antigen Screening.
- Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients.
- Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers.
- Suicidal ideation in prostate Cancer survivors: Understanding the role of physical and psychological health outcomes.
- Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate Cancer treated with sipuleucel-T.
- FGFR3 expression in primary and metastatic urothelial carcinoma of the Bladder.
- MiR-221 promotes the development of androgen independence in prostate Cancer cells via downregulation of HECTD2 and RAB1A.
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision Cancer medicine.
- Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.
- The likelihood of death from prostate Cancer in men with favorable or unfavorable intermediate-risk disease.
- Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate Cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resis...
- Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.
- Population-based patterns of prescription androgen use, 1976-2008.
- Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study.
- Prostate Cancer, version 1.2014.
- Effects of a gift certificate incentive and specialized delivery on prostate Cancer survivors' response rate to a mailed survey: A randomized-controlled trial.
- Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate Cancer starting androgen deprivation therapy (ADT) is associated with s...
- Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codeLivery of siRNA and cisplatin prodrug.
- Reply to clinical predictors of survival in men with castration-resistant prostate Cancer: Evidence that Gleason Score 6 Cancer Can Evolve to Lethal Disease.
- Clinical predictors of survival in men with castration-resistant prostate Cancer: Evidence That Gleason Score 6 Cancer Can Evolve to Lethal Disease.
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate Cancer: Resu...
- Lower baseline proState-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for ProState Adenocarcinoma Treat...
- Defining the optimal approach to the patient with postradiation proState-specific antigen recurrence using outcome data from a prospective randomized trial.
- Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate Cancer.
- Early Detection of Prostate Cancer: AUA Guideline.
- Punctuated evolution of prostate Cancer genomes.
- A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer.
- Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate Cancer.
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate Cancer.
- Single nucleotide polymorphisms and risk of recurrence of Renal-cell carcinoma: a cohort study.
- EZH2 oncogenic activity in castration-resistant prostate Cancer cells is Polycomb-independent.
- Prostate Cancer 2012: where do we stand and where are we heading?
- Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.
- New agents in metastatic prostate Cancer.
- BRAF mutations in metanephric adenoma of the Kidney.
- Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
- Expression differences of circulating microRNAs in metastatic castration resistant prostate Cancer and low-risk, localized prostate Cancer.
- Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate Cancer.
- Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality.
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile.
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer.
- Reply form Authors re: Bertrand Tombal. Continuous Improvement Versus Innovation: The Case for Sipuleucel-T. Eur Urol. In press. DOI:10.1016/j.eururo.2011.11.033.
- The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate Cancer.
- Surrogate endpoints for prostate Cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cance...
- Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer.
- The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature.
- Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer.
- The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness.
- Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men with High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction.
- Prostate Cancer Immunotherapy.
- mRNA expression signature of Gleason grade predicts lethal prostate Cancer.
- Vitamin d receptor protein expression in tumor tissue and prostate Cancer progression.
- Clinical roundtable monograph: new and emerging treatments for advanced prostate Cancer.
- Immunotherapy for the treatment of prostate Cancer.
- SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
- Association of prostate Cancer risk Loci with disease aggressiveness and prostate Cancer-specific mortality.
- Risk of all-cause and prostate Cancer-specific mortality after brachytherapy in men with small prostate size.
- Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate Cancer treated with androgen deprivation therapy.
- Inherited variants in the chemokine CCL2 gene and prostate Cancer aggressiveness in a Caucasian cohort.
- Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate Cancer patients.
- Active surveillance compared with initial treatment for men with low-risk prostate Cancer: a decision analysis.
- Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate Cancer in a Caucasian population.
- Genome-wide association study of prostate Cancer mortality.
- Analysis of the 10q11 Cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.
- Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate Cancer: a postrandomization analysis by...
- Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate Cancer aggressiveness or with efficacy of androgen deprivation therapy.
- A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate Cancer risk and survival.
- Immunohistochemical expression of BRCA1 and lethal prostate Cancer.
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate Cancer.
- Comorbidity, body mass index, and age and the risk of nonprostate-Cancer-specific mortality after a postradiation prostate-specific antigen recurrence.
- Changes in PSA kinetics after DNA vaccine therapy-not so fast!
- Survival following radiation and androgen suppression therapy for prostate Cancer in healthy older men: implications for screening recommendations.
- Evaluating the combined effect of comorbidity and proState-specific antigen kinetics on the risk of death in men after proState-specific antigen recurrence.
- Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate Cancer.
- Activity of dutasteride plus ketoconazole in castration-refractory prostate Cancer after progression on ketoconazole alone.
- Interval to testosterone recovery after hormonal therapy for prostate Cancer and risk of death.
- Polymorphism in endostatin, an angiogenesis inhibitor, and prostate Cancer risk and survival: A prospective study.
- Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate Cancer.
- Androgen receptor regulates a distinct transcription program in androgen-independent prostate Cancer.
- Evaluation of the 8q24 prostate Cancer risk locus and MYC expression.
- Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply.
Schools
The Warren Alpert Medical School Of Brown University
Nyu Bellevue Hospital
Dana Farber Cancer Institute
NihNhlbi
DanaFarber Cancer Institute Chair Executive Committee for Clinical Research
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Colorectal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Boston Herald
- Super Doctor
Education
-
NYU School of Medicine -
Warren Alpert Medical School of Brown University
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1235107871 | |
| NPPES Provider LastName | KANTOFF | |
| NPPES Provider FirstName | PHILIP | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 96.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235107871 |
| Last Name Of The Provider | KANTOFF |
| First Name Of The Provider | PHILIP |
| View All |
Similar Doctors
|
Dr. Craig C. Earle, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ramesh A. Shivdasani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane C. Weeks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William G. Kaelin Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Jackman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Hassett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rameen Beroukhim, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anupam M. Desai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Toni K. Choueiri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter C. Enzinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel A. Freedman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noopur S. Raje, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel G. Stover, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy P. Cooley, MD
This Doctor is OpenDoctor Recommended.
|